



EUROPEAN UNION OF MEDICAL SPECIALISTS (UEMS)
EUROPEAN ACCREDITATION COUNCIL ON CME (EACCME®)

RUE DE L'INDUSTRIE 24, BE- 1040 BRUSSELS
T + 32 2 649 51 64 - F + 32 2 640 37 30

<https://eaccme.uems.eu> - accrreditation@uems.eu

Conflict of Interest Disclosure Form

NAME : Prof. Ludwig Kappos

AFFILIATION: University Hospital Basel

In accordance with criterion 14 of document UEMS 2016/20 "EACCME® criteria for the Accreditation of Live Educational Events (LEEs)", all declarations of potential or actual conflicts of interest, whether due to a financial or other relationship, must be provided to the EACCME® upon submission of the application. Declarations also must be made readily available, either in printed form, with the programme of the LEE, or on the website of the organiser of the LEE. Declarations must include whether any fee, honorarium or arrangement for reimbursement of expenses in relation to the LEE has been provided.

DISCLOSURE

I have no potential conflict of interest to report

I have the following potential conflict(s) of interest to report

Type of affiliation / financial interest

Name of commercial company

Receipt of grants/research supports:

Please see attached the detailed disclosure

Receipt of honoraria or consultation fees:

Participation in a company sponsored speaker's bureau:

Stock shareholder:

Spouse/partner:

Other support (please specify):

Signature:

Date:

Ludwig Kappos' Institution (University Hospital Basel) received in the last 3 years and used exclusively for research support at the Department: steering committee, advisory board and consultancy fees from Actelion, Almirall, Bayer, Biogen, Celgene/Receptos, df-mp, Excemed, Genzyme, Japan Tobacco, Merck, Minoryx, Mitsubishi Pharma, Novartis, Roche, sanofi-aventis, Santhera, Teva, Vianex and royalties for Neurostatus-UHB products.

For educational activities the institution received payments and honoraria from Allergan, Almirall, Baxalta, Bayer, Biogen, CSL-Behring, Desitin, Excemed, Genzyme, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Teva.

L. Kappos has served in the last 24 months as international or local principal investigator for the following drug studies BOLD EXT., EXPAND (Siponimod, Novartis), DECIDE, DECIDE EXT. (Daclizumab HYP, Biogen), ENDORSE (DMF, Biogen), FINGORETT, FTY-UMBRELLA, INFORMS, INFORMS EXT LONGTERMS. (Fingolimod, Novartis), MOMENTUM (Amiselimod, Mitsubishi) OCRELIZUMAB PHASE II EXT., OPERA, ORATORIO and extensions (Ocrelizumab, Roche), REFLEXION (IFN β -1a, Merck), STRATA EXT, TOP (Natalizumab, Biogen), TERIFLUNOMIDE EXT, TERRIKIDS (Teriflunomide, Sanofi-Aventis) and ASCLEPIOS I/II (Ofatumumab, Novartis)

The Research of the MS Center in Basel has been supported by grants from Bayer, Biogen, Novartis, the Swiss MS Society, the Swiss National Research Foundation, the European Union.

In the last 24 months the institution also received grants for patient services from Bayer, Merck and CSL-Behring.

L. Kappos is a member in the Editorial Boards of the following journals: "Journal of Neurology", "Multiple Sclerosis Journal", "Neurology and Clinical Neuroscience", "Multiple Sclerosis and Related Disorders", "Clinical and Translational Neuroscience".

Honoraria and other payments for all these activities have been exclusively used for funding of research at the department.

Basel, August 28th 2018

L. Kappos

Ludwig Kappos, MD
Professor of Neurology
Chair Neurology,
University Hospital
Petersgraben 4
CH-4031 Basel, Switzerland

Phone +41 61 265 44 64
Fax +41 61 265 41 98
eMail: kapposl-pa@usb.ch

Grown up in Athens, Greece Ludwig Kappos obtained his M.D. and a Diploma in Clinical Psychology from the University of Würzburg, Germany, in 1980, where he went on to specialise in Neurology and Neuroimmunology, and became Deputy Chief, Division of Clinical Neurology, Max Planck Society, Clinical Research Unit for Multiple Sclerosis. In 1990 he was elected Head of the Outpatient Department, Neurology/Neurosurgery and since 2008 Chair of Neurology at the University of Basel, Switzerland. Research interests include immunological and molecular studies in neuroimmunological diseases, methodology and conduct of therapeutic studies mainly in the field of MS, standardisation of clinical assessment, development of biomarkers and use of magnetic resonance tomography in elucidating the pathogenesis of inflammatory CNS disease and as tool in monitoring therapeutic studies. Ludwig Kappos serves as chair or member in several steering committees and advisory boards of Clinical Trials and Organizations active in the field of MS and general Neurology. Ludwig Kappos has published more than 670 original papers, reviews and book chapters. He has been awarded with several prizes and honorary doctorates for his scientific contributions.

Basel, August 2018